Clinical trial
A Phase III Randomized Controlled Study Comparing High-dose Rituximab (500 mg/m²) Combined With CHOP Regimen Versus Standard-dose Rituximab (375 mg/m²) Combined With CHOP Regimen in Male Patients With Newly Diagnosed Advanced Diffuse Large B-cell Lymphoma
NCT06573645 is registered in ClinicalTrials.gov with Xia Yi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Randomized Controlled Study Comparing High-dose Rituximab (500 mg/m²) Combined With CHOP Regimen Versus Standard-dose Rituximab (375 mg/m²) Combined With CHOP Regimen in Male Patients With Newly Diagnosed Advanced Diffuse Large B-cell Lymphoma
- Lead sponsor
- Xia Yi
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- August 23, 2024
- Completion date
- July 12, 2027
- Enrollment
- 428 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.